Oscar Segurado

Chief Medical Officer at ASC Therapeutics, a biopharma company focusing on gene editing and gene therapy for Hemophilia A and MSUD, and allogeneic cell therapy for Graft-vs-Host Disease in hematologic malignancies. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain
Author and co-author of over 100 peer-reviewed publications, including Nature, Lancet, Journal of Immunology and Journal of Experimental Medicine, books and medical articles and member of several scientific and medical societies.